<p>Oramed Pharmaceuticals Inc.（纳斯达克代码：ORMP - 获取免费报告）在一月份的空头头寸显著增加。截至 1 月 30 日，空头头寸总计 644,912 股，比 1 月 15 日的 408,588 股增加了 57.8%。目前，公司 2.0% 的股票被做空。根据平均每日成交量 246,539 股，空头头寸比率目前为 2.6 天。</p>
<p>获取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近调整了他们在 ORMP 的持股。HRT Financial LP 在第四季度收购了 Oramed Pharmaceuticals 的新股份，价值约为 131,000 美元。Jane Street Group LLC 在第一季度将其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前拥有 67,173 股该生物技术公司的股票，价值 144,000 美元，此前在上个季度又购买了 17,510 股。美国银行（Bank of America Corp DE）在第三季度将其在 Oramed Pharmaceuticals 的持仓增加了 4.4%。美国银行目前拥有 149,667 股该生物技术公司的股票，价值 395,000 美元，此前在此期间又购买了 6,261 股。Marshall Wace LLP 在第四季度收购了 Oramed Pharmaceuticals 的股份，价值 738,000 美元。最后，BML Capital Management LLC 在第二季度将其在 Oramed Pharmaceuticals 的持股增加了 2.1%。BML Capital Management LLC 目前拥有 3,083,253 股该生物技术公司的股票，价值 6,937,000 美元，此前在上个季度又购买了 62,505 股。当前 12.73% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级变动</h2>
<p>多家券商最近对 ORMP 发布了报告。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Oramed Pharmaceuticals 股票的 “持有（c）” 评级。Wall Street Zen 在 11 月 1 日的研究报告中将 Oramed Pharmaceuticals 的股票评级提升至 “持有”。根据 MarketBeat.com 的数据，一名股票研究分析师对该股票给予了持有评级，Oramed Pharmaceuticals 目前的共识评级为 “持有”。</p>
<p><strong>获取我们最新的 Oramed Pharmaceuticals 股票分析</strong></p>
<h2>Oramed Pharmaceuticals 股票上涨 2.5%</h2>
<p>ORMP 股票在周五开盘价为 3.25 美元。该公司的市值为 1.2935 亿美元，市盈率为 2.58，贝塔值为 1.34。Oramed Pharmaceuticals 的 12 个月低点为 1.82 美元，12 个月高点为 3.71 美元。该公司的 50 日移动平均价格为 3.22 美元，200 日移动平均价格为 2.65 美元。</p>
<h2>Oramed Pharmaceuticals 分红公告</h2>
<p>该公司最近宣布了一项分红，并于 1 月 26 日（星期一）支付。1 月 16 日（星期五）登记在册的股东获得每股 0.25 美元的分红。该分红的除息日期为 1 月 16 日（星期五）。Oramed Pharmaceuticals 的分红支付比率为 19.84%。</p>
<h2>关于 Oramed Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Oramed Pharmaceuticals Inc 是一家临床阶段的生物技术公司，专注于开发专有的口服药物递送系统，最初重点关注糖尿病管理。公司总部位于以色列耶路撒冷，利用其专利的蛋白质包封技术——“口服递送平台”，将注射疗法转变为患者友好的口服制剂。Oramed 的平台旨在保护敏感的蛋白质和肽免受胃肠道降解，从而实现成功的吸收和系统性递送。</p>
<p>该公司的主要候选药物 ORMD-0801 是一种用于 2 型糖尿病患者的口服胰岛素胶囊，目前正在进行第三阶段临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Oramed Pharmaceuticals</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>认为你错过了白银？你错了。这是原因。</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
<li>下一个商品危机（比石油还大？）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Oramed Pharmaceuticals 吗？</h2>
<p>在你考虑 Oramed Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Oramed Pharmaceuticals 并不在名单上。</p>
<p>虽然 Oramed Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Oramed制药

<p>Oramed Pharmaceuticals Inc.（纳斯达克代码：ORMP）在 1 月份的空头头寸增加了 57.8%，截至 1 月 30 日，总计 644,912 股。这大约占公司股票的 2.0%，根据平均每日交易量 246,539 股，空头头寸比率为 2.6 天。机构投资者持有 12.73% 的股份，公司最近宣布每股派息 0.25 美元。ORMP 股票开盘价为 3.25 美元，市值为 1.2935 亿美元，市盈率为 2.58</p>

<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 644,912 shares, an increase of 57.8% from the January 15th total of 408,588 shares. Currently, 2.0% of the company's stock are short sold. Based on an average daily volume of 246,539 shares, the short-interest ratio is presently 2.6 days. Based on an average daily volume of 246,539 shares, the short-interest ratio is presently 2.6 days. Currently, 2.0% of the company's stock are short sold.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc.（纳斯达克代码：ORMP - 获取免费报告）在一月份的空头头寸显著增加。截至 1 月 30 日，空头头寸总计 644,912 股，比 1 月 15 日的 408,588 股增加了 57.8%。目前，公司 2.0% 的股票被做空。根据平均每日成交量 246,539 股，空头头寸比率目前为 2.6 天。</p>
</div><p>Get <strong>Oramed Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of ORMP. HRT Financial LP acquired a new stake in Oramed Pharmaceuticals during the fourth quarter worth approximately $131,000. Jane Street Group LLC lifted its holdings in Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after purchasing an additional 17,510 shares during the last quarter. Bank of America Corp DE increased its position in Oramed Pharmaceuticals by 4.4% during the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company's stock worth $395,000 after buying an additional 6,261 shares during the period. Marshall Wace LLP acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $738,000. Finally, BML Capital Management LLC lifted its holdings in shares of Oramed Pharmaceuticals by 2.1% during the second quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company's stock worth $6,937,000 after buying an additional 62,505 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了他们在 ORMP 的持股。HRT Financial LP 在第四季度收购了 Oramed Pharmaceuticals 的新股份，价值约为 131,000 美元。Jane Street Group LLC 在第一季度将其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前拥有 67,173 股该生物技术公司的股票，价值 144,000 美元，此前在上个季度又购买了 17,510 股。美国银行（Bank of America Corp DE）在第三季度将其在 Oramed Pharmaceuticals 的持仓增加了 4.4%。美国银行目前拥有 149,667 股该生物技术公司的股票，价值 395,000 美元，此前在此期间又购买了 6,261 股。Marshall Wace LLP 在第四季度收购了 Oramed Pharmaceuticals 的股份，价值 738,000 美元。最后，BML Capital Management LLC 在第二季度将其在 Oramed Pharmaceuticals 的持股增加了 2.1%。BML Capital Management LLC 目前拥有 3,083,253 股该生物技术公司的股票，价值 6,937,000 美元，此前在上个季度又购买了 62,505 股。当前 12.73% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages recently issued reports on ORMP. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Oramed Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen raised shares of Oramed Pharmaceuticals to a &#34;hold&#34; rating in a research report on Saturday, November 1st. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals presently has a consensus rating of &#34;Hold&#34;.</p>
<div class="lb-trans"><p>多家券商最近对 ORMP 发布了报告。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Oramed Pharmaceuticals 股票的 “持有（c）” 评级。Wall Street Zen 在 11 月 1 日的研究报告中将 Oramed Pharmaceuticals 的股票评级提升至 “持有”。根据 MarketBeat.com 的数据，一名股票研究分析师对该股票给予了持有评级，Oramed Pharmaceuticals 目前的共识评级为 “持有”。</p>
</div><p><strong>Get Our Latest Stock Analysis on Oramed Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Oramed Pharmaceuticals 股票分析</strong></p>
</div><h2>Oramed Pharmaceuticals Stock Up 2.5%</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 股票上涨 2.5%</h2>
</div><p>ORMP stock opened at $3.25 on Friday. The company has a market cap of $129.35 million, a price-to-earnings ratio of 2.58 and a beta of 1.34. Oramed Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $3.71. The business has a 50 day moving average price of $3.22 and a two-hundred day moving average price of $2.65.</p>
<div class="lb-trans"><p>ORMP 股票在周五开盘价为 3.25 美元。该公司的市值为 1.2935 亿美元，市盈率为 2.58，贝塔值为 1.34。Oramed Pharmaceuticals 的 12 个月低点为 1.82 美元，12 个月高点为 3.71 美元。该公司的 50 日移动平均价格为 3.22 美元，200 日移动平均价格为 2.65 美元。</p>
</div><h2>Oramed Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 分红公告</h2>
</div><p>The company also recently declared a dividend, which was paid on Monday, January 26th. Shareholders of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals's dividend payout ratio is 19.84%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项分红，并于 1 月 26 日（星期一）支付。1 月 16 日（星期五）登记在册的股东获得每股 0.25 美元的分红。该分红的除息日期为 1 月 16 日（星期五）。Oramed Pharmaceuticals 的分红支付比率为 19.84%。</p>
</div><h2>About Oramed Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Oramed Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc 是一家临床阶段的生物技术公司，专注于开发专有的口服药物递送系统，最初重点关注糖尿病管理。公司总部位于以色列耶路撒冷，利用其专利的蛋白质包封技术——“口服递送平台”，将注射疗法转变为患者友好的口服制剂。Oramed 的平台旨在保护敏感的蛋白质和肽免受胃肠道降解，从而实现成功的吸收和系统性递送。</p>
</div><p>The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.</p>
<div class="lb-trans"><p>该公司的主要候选药物 ORMD-0801 是一种用于 2 型糖尿病患者的口服胰岛素胶囊，目前正在进行第三阶段临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Oramed Pharmaceuticals</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Think You Missed Silver? You’re Wrong. Here’s Why.</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>The Next Commodity Crunch (bigger than oil?)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Oramed Pharmaceuticals</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>认为你错过了白银？你错了。这是原因。</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
<li>下一个商品危机（比石油还大？）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Oramed Pharmaceuticals 吗？</h2>
</div><p>Before you consider Oramed Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Oramed Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Oramed Pharmaceuticals 并不在名单上。</p>
</div><p>While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oramed Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oramed 制药公司（NASDAQ: ORMP）在 1 月份的空头头寸增加了 57.8%